CohBar, Inc. (CWBR) |
|
2.7601 -0.12 (-4.16%)
|
06-09 15:00 |
|
Open: |
2.82 |
Pre. Close: |
2.88 |
|
High:
|
2.87 |
Low:
|
2.76 |
|
Volume:
|
31,361 |
Market Cap:
|
8(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 2:44:12 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 5.64 One year: 8.05 |
| Support: |
Support1: 1.5 Support2: 1.24 |
| Resistance: |
Resistance1: 4.83 Resistance2: 6.9 |
| Pivot: |
2.82  |
| Moving Average: |
MA(5): 2.8 MA(20): 2.5
MA(100): 2.04 MA(250): 2.98 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 24.3 %D(3): 24.4 |
| RSI: |
RSI(14): 55.2 |
| 52-week: |
High: 7.17 Low: 1.42 |
| Average Vol(K): |
3-Month: 913 (K) 10-Days: 160 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CWBR ] has closed above bottom band by 48.3%. Bollinger Bands are 219.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.9 - 2.92 |
2.92 - 2.93 |
|
Low:
|
2.7 - 2.71 |
2.71 - 2.73 |
|
Close:
|
2.79 - 2.82 |
2.82 - 2.85 |
|
Company Description |
|
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California. |
Headline News |
Mon, 05 Jun 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CIR, PDCE, CWBR, GHL - CohBar (NASDAQ:CWBR), Cir - Benzinga
Mon, 05 Jun 2023
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors ... - InvestorsObserver
Mon, 05 Jun 2023
2023-06-05 | NDAQ:CWBR | Press Release | CohBar Inc. - Stockhouse Publishing
Sat, 03 Jun 2023
Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE ... - GlobeNewswire
Wed, 31 May 2023
SHAREHOLDER ALERT: The M&A Class Action Firm Continues ... - GlobeNewswire
Tue, 30 May 2023
COHBAR INVESTOR ALERT by the F - GuruFocus.com
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
3 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
15 (%) |
|
% Held by Institutions
|
4.8 (%) |
|
Shares Short
|
43 (K) |
|
Shares Short P.Month
|
49 (K) |
Stock Financials |
|
EPS
|
-3.81 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.63 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-37.1 |
|
Return on Equity (ttm)
|
-60.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.89 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-10 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
-0.73 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.59 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.85 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
